CU-CPT22
Based on 12 publication(s) in Google Scholar
CU-CPT22 is a potent protein complex of toll-like receptor 1 and 2 (TLR1/2) inhibitor, and competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with a Ki of 0.41 µM. CU-CPT22 blocks Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 µM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.08%
- No. CAS: 1416324-85-0
- Fòrmula: C19H22O7
- Peso molecular:362.37
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Pattern Recognition Receptors Library
HY-L237
Publications Citing Use of MedChemExpress (MCE) CU-CPT22
More- Theranostics. 2026 Jan 1;16(6):2952-2983. [Abstract]
- Biomaterials. 2020 May;241:119852. [Abstract]
- Cell Death Discov. 2026 Jun 23. [Abstract]
- Int J Biol Macromol. 2026 Feb:347:150597. [Abstract]
- Life Sci. 2019 May 1:224:212-221. [Abstract]
- Sci Rep. 2023 Nov 9;13(1):19440. [Abstract]
- Curr Pharm Des. 2021;27(44):4464-4476. [Abstract]
- Oral Dis. 2020;00:1-13.
- Cell Tissue Res. 2020 Dec;382(3):585-598. [Abstract]
- Anim Reprod Sci. 2024 Jul:266:107513. [Abstract]
- Biochem Cell Biol. 2023 Aug 1;101(4):303-312. [Abstract]
- Oxid Med Cell Longev. 2019 Apr 28:2019:6527638. [Abstract]
Customer Validation & Images
-
ELISA
-
WB
-
Histological Imaging/Staining
-
IF
-
WB
Actividad biológica
|
TLR1 |
TLR2 |
CU-CPT22 is a toll-like receptor 1 and 2 (TLR1/2) inhibitor with an IC50 of 0.58±0.09 μM. It is demonstrated that CU-CPT22 is able to compete with Pam3CSK4 for binding to TLR1/2 with an inhibition constant (Ki) of 0.41±0.07 μM, which is consistent with its potency observed in the whole cell assay. Increasing the concentration of CU-CPT22 to 6 μM decreases the anisotropy to background levels. It is found that CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. CU-CPT22 is found to have no significant cytotoxicity at various concentrations up to 100 μM in RAW 264.7 cells.? The result demonstrates that CU-CPT22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1416324-85-0
-
Appearance Solid
-
Peso molecular 362.37
-
Fòrmula C19H22O7
-
Color Yellow to orange
-
SMILES
O=C(C(C=C1O)=CC2=CC(OC)=C(O)C(O)=C2C1=O)OCCCCCC
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
Ligand-directed oral lipidic nanoplatform enables sustained ferroptosis and immune reprogramming via multivalent transporter-mediated metronomic delivery. [Abstract]2026 Jan 1;16(6):2952-2983. PMID: 41510171 -
Biomaterials
Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. [Abstract]2020 May;241:119852. PMID: 32120313
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2020 May;241:119852. [Abstract]
The TLR2-MyD88-IKK-IκB-NF-κB signaling pathway was activated in DP7-C-stimulated BMDCs. Furthermore, Western blot results also showed that DP7-C failed to effectively activate MyD88 following treatment with TLR2 inhibitors (C29, CU-CPT22; 8 μM, 2 h), whereas DP7-C still activated MyD88 after treatment with the TLR4 inhibitor TAK242.
-
Cell Death Discov
Secretory LGALS3BP exacerbates sepsis-associated liver dysfunction by activating inflammasome-mediated pyroptosis. [Abstract]2026 Jun 23. PMID: 42336831 -
Int J Biol Macromol
2026 Feb:347:150597. PMID: 41643971 -
Life Sci
Oscillating flow promotes inflammation through the TLR2-TAK1-IKK2 signalling pathway in human umbilical vein endothelial cell (HUVECs). [Abstract]2019 May 1:224:212-221. PMID: 30914314
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Life Sci. 2019 May 1:224:212-221. [Abstract]
WB for detecting the effect of CU-CPT22 (CU CPT, 0.58 μM; 1 h), an inhibitor of TLR2.
-
Sci Rep
Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. [Abstract]2023 Nov 9;13(1):19440. PMID: 37945630 -
Curr Pharm Des
Interaction of Ectodomain of Respiratory Syncytial Virus G Protein with TLR2/ TLR6 Heterodimer: An In vitro and In silico Approach to Decipher the Role of RSV G Protein in Pro-inflammatory Response against the Virus. [Abstract]2021;27(44):4464-4476. PMID: 34279194 -
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.
Representative H&E and F4/80 staining images of saline-injection, CFA-injection and CFA + CU-CPT22 (10 mg/kg; i.p.; administered once prior to TMJOA induction, and twice weekly thereafter) groups' synovium. In CFA-injection mice, the thickness of intimal layer at 2nd (b) and 4th (e) week was markedly higher than that in saline-injection mice (a, d); The intima layer thinned gradually in CTA + CU-CPT22 treated mice (c, f). Analogously, administration of CU-CPT22 (i) significantly inhibited the elevation of F4/80 positive staining in CFA-injection mice (h), compared with that of saline-injection mice (g), which displayed weak expression of F4/80 (Figure j stands for control with negative primary IgG).
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.
The expression of anabolic factors aggrecan (ACAN) and type II collagen (Col2A1) at the 4th week was detected by immunofluorescence. In comparison with CFA-injection mice, CFA + CU-CPT22 (10 mg/kg; i.p.; administered once prior to TMJOA induction, and twice weekly thereafter) treated mice exhibited stronger and homogeneous positive expression of ACAN and Col2A1 on the condylar cartilage.
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Oral Dis. 2020;00:1-13.
Immunoblots detection disclosed that pretreatment of CU-CPT22 (10 μM; pretreated 3 h) significantly reduced the production of TLR2, NF-κB p65, as well as catabolic factors (MMP3, MMP13) and inflammatory factors (TNF-α, COX-2) in chondrocytes induced by IL-1β (10 ng/mL).
-
Cell Tissue Res
Pyruvate kinase M2 activation protects against the proliferation and migration of pulmonary artery smooth muscle cells. [Abstract]2020 Dec;382(3):585-598. PMID: 32719938 -
Anim Reprod Sci
The roles of Braun Lipoprotein in inducing tolerance of bovine endometrium infected by Escherichia coli. [Abstract]2024 Jul:266:107513. PMID: 38843662
CU-CPT22 purchased from MedChemExpress. Usage Cited in: Anim Reprod Sci. 2024 Jul:266:107513. [Abstract]
Effect of TLR2 on the release of inflammatory mediators in EECs infected with LPS and E. coli in the presence of BLP. EECs were pretreated with the TLR2 inhibitor, CU-CPT22 (10 µM), before treatment for 4 h. EECs were treated with LPS (1 μg/mL) and BLP (1 μg/mL) in combination, or untreated (A-C). EECs were infected with JE5505 (1 × 106 CFU) in combination with BLP (1 μg/mL) or left uninfected (D-F). Release of IL-6, IL-8, and IL-10 into the supernatant of EECs cultures was analyzed by ELISA, 12 h after treatment.
-
Biochem Cell Biol
2023 Aug 1;101(4):303-312. PMID: 36927169 -
Oxid Med Cell Longev
Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the MicroRNA155-5p/SHIP1 Pathway. [Abstract]2019 Apr 28:2019:6527638. PMID: 31182996
Solvente y solubilidad
DMSO : ≥ 125 mg/mL (344.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
RAW 264.7 cells are planted in 6-well plates at 1,000,000 cells per well with 3 mL of medium and grown for 24 h at 37°C in a 5% CO2 humidified incubator. After 24 h, non-adherent cells and media are removed and replaced with fresh RPMI 1640 medium (3 mL/well). Two wells of adherent macrophages are treated with Pam3CSK4 (300 ng/mL) as the positive control, two wells are treated with 8 μM CU-CPT22, and the other two wells are treated with 8 μM compound DMSO. Plates are then incubated for an additional 24 h. The medium is removed, the cells are washed with PBS (3×1 mL), the plate is put on ice, then 500 μL of lysis buffer is added to each well. The production of the cytokine interleukin-1β (IL-1β) and TNF-α is quantified with enzyme-linked immunosorbent assays (ELISA). The cytokine level in each sample is determined in duplicate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (622 KB)
- English - EN (622 KB)
- Français - FR (622 KB)
- Deutsch - DE (622 KB)
- Norwegian - NO (622 KB)
- Español - ES (622 KB)
- Swedish - SV (622 KB)
- Italian - IT (622 KB)
- Korean - KR (622 KB)
- Portuguese - PT (622 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7596 mL | 13.7981 mL | 27.5961 mL | 68.9903 mL |
| 5 mM | 0.5519 mL | 2.7596 mL | 5.5192 mL | 13.7981 mL | |
| 10 mM | 0.2760 mL | 1.3798 mL | 2.7596 mL | 6.8990 mL | |
| 15 mM | 0.1840 mL | 0.9199 mL | 1.8397 mL | 4.5994 mL | |
| 20 mM | 0.1380 mL | 0.6899 mL | 1.3798 mL | 3.4495 mL | |
| 25 mM | 0.1104 mL | 0.5519 mL | 1.1038 mL | 2.7596 mL | |
| 30 mM | 0.0920 mL | 0.4599 mL | 0.9199 mL | 2.2997 mL | |
| 40 mM | 0.0690 mL | 0.3450 mL | 0.6899 mL | 1.7248 mL | |
| 50 mM | 0.0552 mL | 0.2760 mL | 0.5519 mL | 1.3798 mL | |
| 60 mM | 0.0460 mL | 0.2300 mL | 0.4599 mL | 1.1498 mL | |
| 80 mM | 0.0345 mL | 0.1725 mL | 0.3450 mL | 0.8624 mL | |
| 100 mM | 0.0276 mL | 0.1380 mL | 0.2760 mL | 0.6899 mL |
CU-CPT22 Related Classifications
HY-108471 Related Classifications
Powered by Bioz